52 results about "Recombinant salmon calcitonin" patented technology

A pharmaceutical composition for oral delivery of a peptide is in the form of a lamination having at least two layers. The first layer of the lamination includes at least one pharmaceutically acceptable pH-lowering agent. The second layer includes a therapeutically effective amount of the peptide. The composition also includes at least one absorption enhancer effective to promote bioavailability of the peptide, which is preferably in the second layer, and an enteric coating surrounding the lamination. In a preferred dosage form of a tablet, a water-soluble coating is applied between the lamination and enteric coating which substantially prevents contact between the pH-lowering agent and the enteric coating. In a preferred embodiment, the peptide is salmon calcitonin, the pH-lowering agent is citric acid, and the absorption enhancer is lauroyl l-carnitine.

The invention discloses a polypeptide or protein nanoparticle based on hydrogen-bonded complexation and a preparation method and application thereof. The nanoparticles comprise a polyphenol compound carrier such as tannic acid as a hydrogen bond donor, a polypeptide or a protein drug such as a glucagon-like peptide as a hydrogen bond acceptor 1 analog (exenatide), salmon calcitonin or insulin, etc., and chitosan, polyvinylpyrrolidone or hyaluronic acid, etc. coated on that surface of the particle as stabilizer and/or functional molecule. The nanoparticles of the invention have extremely high encapsulation efficiency and drug loading capacity, and the prepared therapeutic polypeptide or protein drug nanoparticles are suitable for oral delivery or subcutaneous injection application, and havegreat application prospect.

The invention discloses a method for preparing salmon calcitonin acetate by fragment condensation, which comprises the following steps: 1) synthesizing fragment sequences of salmon calcitonin (1st-10th, 11th-23rd, 24th-32nd or 24th-31st amino acids) on a solid-phase vector by solid-phase synthesis; 2) sequentially coupling the fragment in the liquid phase to form full-protection salmon calcitonin; and 3) cracking the full-protection salmon calcitonin to obtain salmon calcitonin crude peptides, and carrying out high-efficiency liquid-phase purification salt exchange to obtain the salmon calcitonin acetate pure peptides. The method for preparing salmon calcitonin acetate by combining solid/liquid phase and fragment condensation enhances the yield and purity, and is low in cost and beneficial to large-scale production.

The invention provides a fusion polypeptide transgene sequence for calcitonin-gene-related peptide and salmon calcitonin and a transgene engineering strain thereof, and relates to a fusion polypeptide transgene sequence and a transgene engineering strain. The invention solves the problem that: the prior calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide are not suitable for industrialized production with microbes and animals as reactors. The calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide transgene sequence is shown as SEQ ID NO.1. The calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide transgene engineering strain is an agrobacterium containing fusion gene plasmids, wherein the fusion genes in the plasmids are shown as SEQ ID NO.1. The calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide transgene engineering strain can be used for mediating a plant with the cost of the engineering strain being 1/10 to 1/50 of that of bacillus coli.

The present invention is fusion protein constituted through fusing phycocyanin beta-subunit gene in the upstream of human and salmon calcitonin chimera gene. The fusion protein has length 648 bp, molecular weight 23 KDa, amino acid sequence with 100 % homology with the sequence shown in SEQ No. 2 and polypeptide with 213 residues; and has prokaryotic expression vector with preservation number of CCTCC1261. The calcitonin chimera gene has length 102 bp; and the phycocyanin beta-subunit gene is cpcB gene of length 519 bp and polypeptide coding 171 amino acid residues. The constitution of the fusion protein needs no processing and purification, and this ensures the high expression amount of the calcitonin, increases the stability in clinical application, lowers the antigenicity of calcitonin and raises its bioactivity.

The invention relates to a salmon calcitonin soluble microneedle patch and a preparation method thereof. The salmon calcitonin soluble microneedle patch is composed of a substrate and a needle body, the needle body is prepared from a mixed solution of salmon calcitonin, dextran and trehalose, the mass ratio of salmon calcitonin to dextran to trehalose is 1:5-20:4-8; and the substrate is prepared from a solution of a water soluble polymer material. The salmon calcitonin soluble microneedle patch has the advantages of good mechanical strength, good stability, good effect of reducing blood calcium and high bioavailability. The addition of the trehalose can facilitates the improvement of the stability of the salmon calcitonin and the transdermal drug release efficiency of a microneedle, the bioavailability of the salmon calcitonin is improved, and a higher effect of reducing the blood calcium can be achieved.

The invention provides calcitonin gene-related peptide and salmon calcitonin fusion polypeptide, relating to fusion polypeptide. In order to generate a product containing both calcitonin and the calcitonin gene-related peptide, the invention provides the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide. The amino acid sequence of the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide is shown in SEQ ID No:1; moreover, C-terminal amidation is carried out to the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide. Experiments verify that the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide preserve respective activities of the calcitonin gene-related peptide and salmon calcitonin.

The invention belongs to the technical field of medicines and relates to a salmon calcitonin-phospholipid complex and its lipid nanoparticle and preparation method. The salmon calcitonin-phospholipid complex and its lipid nanoparticle can improve drug lipid solubility, have a certain intestinal adhesion, can be easily absorbed through intestinal mucosa and can prevent drug degradation caused by gastrointestinal tract protease. The lipid nanoparticle of the salmon calcitonin-phospholipid complex comprises the salmon calcitonin-phospholipid complex, a lipid material, a surfactant and water and is prepared through a film dispersion method. The water-soluble drug nanoparticle obtained through the preparation method has a high drug oil-liquid distribution coefficient and good membrane permeability and improves oral bioavailability. The preparation method has simple processes.

The invention discloses transgenic salmon calcitonin yeast, a preparation method and the application. The salmon calcitonin is expressed in a eukaryotic system of Saccharomyces cerevisiae. The fermentation technology of Saccharomyces cerevisiae is mature with a higher expression and the Saccharomyces cerevisiae can be eaten directly; the obtained transgenic salmon calcitonin Saccharomyces cerevisiae can be taken orally without purification. The invention reduces the production cost and realizes oral administration of calcitonin.

A salmon's calcitonin gene synthesized by plant preference codon, its fusion gene configurator, the recombinant expression carrier carrying said configurator, the plant cell converted by said expression carrier, the transgenic plant and its descendant generated by said converted cells for expressing said salmon's calcitonin, and the process for detecting the nucleic acid sequence and polypeptide of salmon's calcitonin in specimen are disclosed.

The invention belongs to the field of analytical chemistry, and relates to a method for determining the content of benzalkonium chloride in a salmon calcitonin nasal spray by an HPLC method. A chromatographic column adopted in the method adopts octadecyl silane chemically bonded silica as filler, and an optimized mobile phase A and a mobile phase B are adopted for isocratic elution; and a drug isa polypeptide nasal spray, and a bacteriostatic agent is benzalkonium chloride. According to the method, the content of the bacteriostatic agent in the salmon calcitonin nasal spray of polypeptide drugs can be conveniently and accurately determined; and the method is easy and convenient to operate, rapid, accurate, high in sensitivity, good in repeatability, mild in condition and small in trailingfactor, through systematic methodology verification, it is proved that the method is applied to the determination of the content of the benzalkonium chloride in the salmon calcitonin nasal spray, theinspection results are accurate and reliable, and great significance to the quality control of the salmon calcitonin nasal spray is achieved.

The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.

A mufti-organ gene profiling analysis of the results of an administration to a subject of salmon calcitonin or a parathyroid hormone analogue provides biomarkers of calcitonin treatment efficacy and parathyroid hormone or parathyroid hormone analogue treatment efficacy. Among the biomarkers are the expression profiles of the genes for Y-box binding protein, BMPs, FGFs, IGFs, VEGF, &x3B1;-2-HS glycoprotein (AHSG), OSF, nuclear receptors (steroid/thyroid family) and others. The results obtained support the anabolic effect of salmon calcitonin on bone metabolism.

The invention relates to a novel salmon calcitonin analogue and a preparation method thereof. Compared with a natural salmon calcitonin, the chemical stability of a compound provided by the invention is improved and the pharmacological activity of the natural salmon calcitonin is kept. The salmon calcitonin analogue provided by the invention has the following chemical structure.

The invention discloses a method for preparing salmon calcitonin. The method provided by the invention comprises the following steps: (1) importing a recombinant vector containing an expression cassette into a receiver plant, so as to obtain a transgenic plant, wherein the expression cassette comprises the following elements from top to bottom in sequence: a promoter of a plant oil body protein gene, a fusion gene and a termination sequence; the fusion gene comprises a segment III used for coding a protein tag, a segment I used for coding a plant oil body protein, a digestion identification sequence of protease and a nucleic acid molecule of a precursor used for coding salmon calcitonin; (2) taking seeds of the transgenic plant for extraction of oil bodies; (3) purifying a fusion protein from the oil bodies by utilizing the protein tag; (4) digesting the fusion protein with protease; (5) separating salmon calcitonin; (6) acetifying; (7) performing desalting. Salmon calcitonin with comparatively high biological activity can be obtained by utilizing the method provided by the invention. Therefore, the method provided by the invention has an important application value.